IGHV status significantly influences CLL prognosis, with mutated IGHV linked to longer survival and unmutated IGHV to shorter progression-free survival. NGS enhances IGHV analysis by overcoming Sanger ...
Abbreviations: BR, bendamustine plus rituximab; CLL, chronic lymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; IGHV, immunoglobulin heavy-chain variable region; SLL ...
The BCR IGH is coded for by multiple genes, including VDJ genes. Only productive and functional IG rearrangements are retained in B-cells. IGH gene rearrangements in B-cells undergo additional somatic ...
Combined ID-IGHV report at time of diagnosis conveniently provides additional prognostic information while also enabling future MRD monitoring in patients SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- ...
Brukinsa showed superior PFS and ORR compared to Rituxan in CLL/SLL patients, with a 71% risk reduction in progression or death. Brukinsa's efficacy was consistent across various risk factors, ...
Chronic lymphocytic leukemia (CLL) is typically a disease of the elderly, but not exclusively. It does occasionally strike younger patients. In the U.S., the median age of individuals at diagnosis is ...
MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...
Acalabrutinib-venetoclax combinations significantly improved PFS over CIT in treatment-naïve CLL patients, with a 35% risk reduction in disease progression or death. The ...
Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of cases, patients with CLL will develop lymphoma, a complication known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback